CETSA MS profiling for a comparative assessment of FDA approved antivirals repurposed for COVID-19 therapy identifies Trip13 as a Remdesivir off-target
T. Friman, A. Chernobrovkin, D. Martinez Molina, L. H. Arnold
This study uses CETSA MS to compare host targets of FDA-approved antivirals, identifying Trip13 as a Remdesivir off-target.
bioRxiv · Jul 19, 2020Pharmacology & Toxicology